Riskpilot← Back to searchSign inGet full accessTERAPIVAKTEN AS
ASActiveOrg 912891739Åsplundvegen 31, 2070 RåholtOther human health activities n.e.c. · NACE 8699Est. 20132 employees
Revenue 2024
NOK 1,5M
+160% vs 2023
EBITDA margin
10.6%
+9174% vs 2023
Equity ratio
26.5%
Financial strength
Net profit 2024
NOK 108K
+6465% vs 2023
| Revenue | NOK 1,5M | +160% |
| EBITDA | NOK 154K | +9174% |
| Net profit | NOK 108K | +6465% |
| Total assets | NOK 324K | +317% |
| Equity | NOK 86K | +20% |
| Employees | 2 | — |
Legal name
TERAPIVAKTEN AS
Org number
912891739
Legal form
Aksjeselskap
NACE code
8699 · Other human health activities n.e.c.
Founded
31. desember 2013
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Formidling av helse og sosialtjenester, samt utvikling av slike tjenester. Arbeid innen rusomsorg, psykisk helsevern og annen avhengighets problematikk.
Address
Åsplundvegen 31, 2070 Råholt
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 24 | 412 | 306 | 106 | 269 | 841 | 522 | 532 | 559 | 1 454 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −8 | −13 | −11 | −774 |
| EBITDA | 8 | −41 | 4 | −1 | 2 | 38 | 73 | 22 | −34 | −2 | 154 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −18 |
| EBIT | 8 | −41 | 4 | −1 | 2 | 38 | 73 | 22 | −34 | −2 | 137 |
| Net financials | 0 | −2 | −0 | 0 | −1 | −2 | 0 | 0 | 0 | 0 | 1 |
| Profit before tax | 8 | −43 | 4 | −1 | 1 | 37 | 73 | 22 | −34 | −2 | 138 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | 16 | 5 | −5 | −0 | 30 |
| Net profit | 8 | −43 | 4 | −1 | 1 | 37 | 57 | 17 | −30 | −2 | 108 |
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 38 | 0 | 8 | 3 | 3 | 40 | 273 | 204 | 71 | 78 | 324 |
| Equity | 30 | −13 | −9 | −10 | −9 | 28 | 85 | 103 | 73 | 71 | 86 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | −3 | 83 |
| Short-term debt | 8 | 13 | 16 | 12 | 12 | 12 | 188 | 96 | −2 | 9 | 155 |
| Total debt | 8 | 13 | 16 | 12 | 12 | 12 | 188 | 101 | −2 | 6 | 238 |
EBITDA margin
10.6%
This company
15.8%
Market median
-33% vs market
20142024
Equity ratio
26.5%
This company
38.2%
Market median
-31% vs market
20142024
Return on equity
126.0%
This company
18.4%
Market median
+585% vs market
20142024
Net profit margin
7.4%
This company
8.1%
Market median
-9% vs market
20142024
Asset turnover
4.49×
This company
1.12×
Market median
+301% vs market
20142024
Debt / equity
2.77×
This company
0.62×
Market median
-347% vs market
20142024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2013-12-06 – 2014-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2021 | — | — | |
| Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Remmes Holding As | Company | 90.0% | 90.0% | 2022 |
| Individual | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Remmes Holding As
TERAPIVAKTEN AS Board members of TERAPIVAKTEN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Frøydis Sandbakken Remme | Board of Directors | 0 companies |
| Ove André Remme | Chairman | 0 companies |